Biomed Valley Discoveries Announces First Patient Dosed in Phase 2 Study of Its First-in-Class ERK 1/2 Inhibitor Ulixertinib in People with Histiocytosis Biomed Valley Discoveries today announced that the first patient has been dosed in a Phase 2 study of ulixertinib for the treatment of histiocytosis.